Hubei Biocause Pharmaceutical Third Quarter 2024 Earnings: EPS: CN¥0.006 (vs CN¥0.005 loss in 3Q 2023)
Hubei Biocause Pharmaceutical (SZSE:000627) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥4.57b (down 41% from 3Q 2023).
- Net income: CN¥31.9m (up from CN¥25.6m loss in 3Q 2023).
- Profit margin: 0.7% (up from net loss in 3Q 2023).
- EPS: CN¥0.006 (up from CN¥0.005 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hubei Biocause Pharmaceutical shares are down 5.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Hubei Biocause Pharmaceutical that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Hubei Biocause Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:000627
Hubei Biocause Pharmaceutical
Primarily provides life and motor insurance products in China.
Slightly overvalued with imperfect balance sheet.
